{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T08:42:29Z","timestamp":1761986549608,"version":"build-2065373602"},"reference-count":9,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["annallergy.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Allergy, Asthma & Immunology"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1016\/j.anai.2020.11.009","type":"journal-article","created":{"date-parts":[[2020,11,21]],"date-time":"2020-11-21T19:16:39Z","timestamp":1605986199000},"page":"206-207","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Non-neutralizing antibodies and limitations of serologic testing for severe acute respiratory syndrome coronavirus 2 in patients receiving immunoglobulin replacement products"],"prefix":"10.1016","volume":"126","author":[{"given":"Deepti Vellaichamy","family":"Manian","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chelsee","family":"Jensen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elitza S.","family":"Theel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John R.","family":"Mills","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Avni","family":"Joshi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.anai.2020.11.009_bib1","doi-asserted-by":"crossref","first-page":"260","DOI":"10.2500\/ajra.2013.27.3899","article-title":"Common variable immunodeficiency","volume":"27","author":"Tam","year":"2013","journal-title":"Am J Rhinol Allergy"},{"key":"10.1016\/j.anai.2020.11.009_bib2","doi-asserted-by":"crossref","unstructured":"Fung M, Babik JM. COVID-19 in immunocompromised hosts: what we know so far [e-pub ahead of print]. Clin Infect Dis. https:\/\/doi.org\/10.1093\/cid\/ciaa863, accessed August 15, 2020.","DOI":"10.1093\/cid\/ciaa863"},{"issue":"1","key":"10.1016\/j.anai.2020.11.009_bib3","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.jaci.2020.04.013","article-title":"A\u00a0possible role for B cells in COVID-19? Lesson from patients with agammaglobulinemia","volume":"146","author":"Quinti","year":"2020","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"6","key":"10.1016\/j.anai.2020.11.009_bib4","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1038\/s41577-020-0333-2","article-title":"SARS-CoV-2-reactive T cells in patients and healthy donors","volume":"20","author":"Pia","year":"2020","journal-title":"Nat Rev Immunol"},{"issue":"7","key":"10.1016\/j.anai.2020.11.009_bib5","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1016\/j.cell.2020.05.015","article-title":"Targets of T cell responses to SARS-CoV-2 coronavirus in humans with COVID-19 disease and unexposed individuals","volume":"181","author":"Grifoni","year":"2020","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.anai.2020.11.009_bib6","doi-asserted-by":"crossref","first-page":"15","DOI":"10.3390\/biom6010015","article-title":"The production processes and biological effects of intravenous immunoglobulin","volume":"6","author":"Barahona Afonso","year":"2016","journal-title":"Biomolecules"},{"issue":"8","key":"10.1016\/j.anai.2020.11.009_bib7","doi-asserted-by":"crossref","first-page":"571","DOI":"10.2217\/imt-2020-0095","article-title":"Currently available intravenous immunoglobulin contains antibodies reacting against severe acute respiratory syndrome coronavirus 2 antigens","volume":"12","author":"Diez","year":"2020","journal-title":"Immunotherapy"},{"key":"10.1016\/j.anai.2020.11.009_bib8","doi-asserted-by":"crossref","unstructured":"Wu F, Wang A, Liu M, et\u00a0al. Neutralizing antibody responses to SARS-CoV-2 in a COVID-19 recovered patient cohort and their implications. Available at: https:\/\/www.medrxiv.org\/content\/10.1101\/2020.03.30.20047365v2. Accessed August 15, 2020.","DOI":"10.1101\/2020.03.30.20047365"},{"key":"10.1016\/j.anai.2020.11.009_bib9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.virol.2020.05.006","article-title":"Recovery of severely ill COVID-19 patients by intravenous immunoglobulin (IVIG) treatment: a case series","volume":"548","author":"Mohtadi","year":"2020","journal-title":"Virology"}],"container-title":["Annals of Allergy, Asthma & Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1081120620312114?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1081120620312114?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T13:26:22Z","timestamp":1761053182000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1081120620312114"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2]]},"references-count":9,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,2]]}},"alternative-id":["S1081120620312114"],"URL":"https:\/\/doi.org\/10.1016\/j.anai.2020.11.009","relation":{},"ISSN":["1081-1206"],"issn-type":[{"type":"print","value":"1081-1206"}],"subject":[],"published":{"date-parts":[[2021,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Non-neutralizing antibodies and limitations of serologic testing for severe acute respiratory syndrome coronavirus 2 in patients receiving immunoglobulin replacement products","name":"articletitle","label":"Article Title"},{"value":"Annals of Allergy, Asthma & Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.anai.2020.11.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 American College of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}